20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Alcohol Use and Co-Use of Other Substances Among Pregnant Females Aged 12–44 Years — United States, 2015–2018

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Drinking alcohol during pregnancy can cause fetal alcohol spectrum disorders, including birth defects, behavioral disorders, and impaired cognitive development ( 1 ). Little is known about the co-use of other substances by females who drink during pregnancy. CDC used 2015–2018 data from the National Survey on Drug Use and Health (NSDUH) to estimate the overall and trimester-specific prevalence of self-reported drinking in the past 12 months, current drinking, and binge drinking, overall and by trimester, and the co-use of other substances among pregnant females aged 12–44 years. Past drinking (12 months) was reported by 64.7% of pregnant respondents. Current drinking (at least one drink in the past 30 days) was reported by 19.6% of respondents who were in their first trimester of pregnancy and 4.7% of respondents who were in their second or third trimester. Binge drinking (consuming four or more drinks on at least one occasion in the past 30 days) was reported by 10.5% of first trimester respondents and 1.4% of second or third trimester respondents. Overall, 38.2% of pregnant respondents who reported current drinking also reported current use of one or more other substances. The substances used most with alcohol were tobacco and marijuana. Self-reported drinking prevalence was substantially lower among second or third trimester respondents than among first trimester respondents. The American College of Obstetricians and Gynecologists (ACOG) recommends alcohol use and substance use disorders screening for all females seeking obstetric-gynecologic care and counseling patients that there is no known safe level of alcohol use during pregnancy ( 2 ). NSDUH is a nationwide survey that uses multistage and area probability sampling to provide information on tobacco, alcohol, and drug use, and on mental health and other health-related issues, among U.S. civilian, noninstitutionalized persons aged ≥12 years. Surveys are conducted in respondents’ homes and use computer-assisted interviewing methods. Female respondents report whether they are currently pregnant and the trimester of pregnancy at the time of the interview. Weighted response rates for 2015–2018 ranged from 66.6% to 69.3%.* This report focuses on past 12 months drinking, current drinking and binge drinking among pregnant respondents. Drinking alcohol during pregnancy and binge drinking in any population are two measures of excessive drinking. † In addition, this report provides estimates of the prevalence of co-use of other substances among respondents who drank alcohol. Respondents who reported ever having an alcoholic beverage were asked how long it had been since they last drank an alcoholic beverage. This report also examined past 12 months and past 30 days use of other substances, including tobacco (i.e., cigarettes, cigars, smokeless tobacco, and pipes), marijuana, opioids (prescription pain reliever misuse and heroin use), and “other substances,” which included cocaine, hallucinogens, inhalants, methamphetamines, and the misuse § of sedatives, stimulants, and tranquilizers. Other substances were grouped as one category because of the small number of pregnant females who reported using them. Data were weighted to adjust for nonresponse and to generate nationally representative estimates. Prevalence estimates and 95% confidence intervals (CIs) for past 12 months drinking, current drinking, and binge drinking were calculated overall and by sociodemographic and pregnancy characteristics (age, race/ethnicity, income, marital status, education, employment status, insurance status, county urban/rural status, and trimester of pregnancy). Prevalence estimates and 95% CIs for past 12 months and current drinking alone and with co-occurring substance use among pregnant respondents also were calculated. Analyses were conducted using SAS (version 9.4; SAS Institute) with SUDAAN (version 11.0; RTI International) to account for the complex sampling method used in NSDUH.This activity was reviewed by CDC and conducted consistent with CDC policies and procedures. ¶ Among 99,618 female respondents aged 12–44 years, 3,006 (3%) reported a current pregnancy. Among pregnant respondents, past 12 months drinking, current drinking, and binge drinking prevalence estimates were 64.7%, 9.8%, and 4.5%, respectively (Table 1). Past 12 months drinking was reported by 76.1% of first trimester respondents and 59.8% of second or third trimester respondents; current drinking by 19.6% of first trimester respondents and 4.7% of second or third trimester respondents; and binge drinking by 10.5% of first trimester respondents and 1.4% of second or third trimester respondents (p<0.001 for all comparisons) (Table 1; Figure). TABLE 1 Weighted prevalence of past 12 months and past 30 days drinking and past 30 days binge drinking in 3,006 pregnant females aged 12–44 years, by selected characteristics — National Survey on Drug Use and Health, United States, 2015–2018 Characteristic % (95% CI) Past 12 months drinking* Past 30 days drinking* Past 30 days binge drinking* Overall 64.7 (62.1–67.3) 9.8 (8.5–11.1) 4.5 (3.7–5.4) Age group (yrs) <18 39.0 (27.3–52.1) —† —† 18–25 61.2 (58.0–64.3) 9.9 (7.9–12.2) 6.0 (4.5–8.1) 26–34 68.2 (64.2–72.0) 9.4 (7.6–11.5) 3.9 (2.9–5.3) ≥35 63.1 (55.5–70.1) 11.1 (7.3–16.6) § —† Race/Ethnicity White, non-Hispanic 74.9 (71.4–78.0) 9.9 (8.2–11.8) 4.0 (3.0–5.3) Black, non-Hispanic 56.7 (51.0–62.3) 13.7 (9.8–18.9) 7.0 (4.6–10.9) § Hispanic 48.0 (42.2–53.7) 7.0 (4.5–10.7) § —† Other 52.9 (44.0–61.7) 8.4 (4.8–14.4) —† Income § <$20,000 50.5 (45.2–55.8) 9.7 (7.3–12.8) 6.3 (4.7–8.3) $20,000–$74,999 61.6 (57.9–65.2) 8.7 (7.0–10.8) 3.9 (2.8–5.4) ≥$75,000 78.3 (74.0–82.1) 11.4 (9.2–14.0) 4.3 (3.0–6.0) Marital status ¶ Married 66.2 (62.2–70.0) 9.0 (7.3–11.0) 3.1 (2.2–4.3) Not married 63.6 (59.9–67.1) 11.0 (9.1–13.3) 6.5 (5.0–8.4) Education ¶ ≤High school 49.2 (45.3–53.0) 8.9 (6.9–11.4) 5.3 (3.8–7.6) >High school 73.3 (70.0–76.3) 10.3 (8.8–12.0) 4.0 (3.1–5.2) Employment ¶ Full time 76.3 (73.1–79.1) 11.6 (9.7–13.9) 4.6 (3.4–6.2) Part time 62.5 (57.2–67.5) 8.7 (5.8–12.8) 3.4 (1.9–6.2) § Unemployed/Other** 53.5 (49.3–57.7) 8.3 (6.4–10.6) 4.8 (3.4–6.6) Insurance Medicaid 54.9 (51.3–58.5) 7.6 (6.0–9.5) 3.8 (2.8–5.0) Private 73.9 (70.2–77.3) 10.6 (8.6–13.0) 4.0 (3.0–5.5) Uninsured/Other †† 53.2 (46.2–60.1) 13.5 (9.4–18.9) 9.5 (5.7–15.4) § Urban/Rural §§ Metropolitan 65.7 (61.6–69.5) 10.3 (8.4–12.7) 3.8 (2.7–5.4) Micropolitan 64.5 (60.6–68.2) 9.3 (7.1–12.0) 4.9 (3.7–6.6) Rural 61.0 (55.8–66.0) 8.3 (5.9–11.7) 6.3 (3.9–9.8) § Trimester ¶¶ First 76.1 (72.7–79.3) 19.6 (16.8–22.7) 10.5 (8.5–13.0) Second or third 59.8 (56.5–63.1) 4.7 (3.5–6.4) 1.4 (0.9–2.1) Abbreviation: CI = confidence interval. * Past 12 months use regardless of whether there was also past 30 days use; past 30 days drinking regardless of whether there was also past 30 days binge drinking; binge drinking = consuming four or more drinks on at least one occasion in the past 30 days. † Estimates are not presented because the relative standard error was >30%. § Estimate might be unstable because the relative standard error is 20%–30%. ¶ The age group <18 years was omitted for income, marital status, education, and employment ** Other = those not in the labor force. †† Other insurance not otherwise specified. §§ https://www.ers.usda.gov/data-products/rural-urban-continuum-codes. ¶¶ Overall, 1.3% of females reported an unknown trimester of pregnancy and were not included in the table. FIGURE Weighted prevalence of past 12 months drinking, past 30 days drinking, and past 30 days binge drinking* among pregnant females † aged 12–44 years (N = 3,006), by trimester — National Survey on Drug Use and Health, United States, 2015–2018 * For females, binge drinking = four or more drinks per occasion. † Overall, 1.3% of pregnant females reported an unknown trimester of pregnancy and were not included in the figure. The figure is a bar chart showing the percentages of females within each of three groupings reflecting frequency of use, who drank during their first trimester of pregnancy, and similarly, those who drank during the second or third trimester (combined). Among respondents who were pregnant and reported drinking in the past 12 months, 41.7% also reported using at least one other substance in the past 12 months. The most commonly reported substances were tobacco (30.3%), marijuana (21.9%), and opioids (7.0%) (Table 2). Among respondents who reported current drinking, 38.2% reported using at least one other substance, most commonly tobacco (28.1%) and marijuana (20.6%) (Table 2) TABLE 2 Weighted prevalence of substance use patterns (past 12 months and past 30 days) in pregnant females aged 12–44 years (N = 3,006*) who drank alcohol in the past 12 months (n = 1,851*) or the past 30 days (n = 282*) — National Survey on Drug Use and Health, United States, 2015–2018 Substance use pattern % (95% CI) Past 12 months drinking† Past 30 days (current) drinking All pregnant females (N = 3,006*) Any alcohol use 64.7 (62.1–67.3) 9.8 (8.5–11.1) Alcohol use only 37.7 (35.7–39.7) 6.0 (5.0–7.2) Alcohol and ≥1 additional substance 27.0 (25.1–29.0) 3.7 (2.9–4.7) Other substances used§ Tobacco¶ 19.6 (18.0–21.3) 2.7 (2.1–3.6) Marijuana 14.2 (12.3–16.3) 2.0 (1.4–2.8) Opioids** 4.5 (3.5–5.8) —†† Other†† 6.2 (5.0–7.7) —†† Pregnant females who drank in the past 12 months (n = 1,851*) or in the past 30 days (n = 282*) Alcohol use only 58.3 (56.0–60.6) 61.8 (53.9–69.2) Alcohol and ≥1 additional substance 41.7 (39.4–44.0) 38.2 (30.8–46.1) Other substances used§ Tobacco¶ 30.3 (28.0–32.8) 28.1 (21.7–35.6) Marijuana 21.9 (19.0–25.0) 20.6 (14.5–28.3) Opioids** 7.0 (5.5–8.9) —†† Other§§ 9.76 (7.8–11.8) —†† Abbreviation: CI = confidence interval. * Unweighted. † Past 12 months use, regardless of whether there was also drinking in the past 30 days (current drinking). § Not mutually exclusive. ¶ Includes cigarettes, cigars, or smokeless tobacco. ** Includes prescription pain reliever misuse and heroin use. †† Estimates are not presented because the relative standard error was >30%. §§ Includes use of cocaine, hallucinogens, inhalants, methamphetamines, and the misuse of sedatives, stimulants, and tranquilizers. Overall, 19.6% of respondents who were pregnant reported past 12 months drinking and tobacco use, 14.2% reported past 12 months drinking and marijuana use, 4.5% reported past 12 months drinking and opioid use, 2.7% reported current drinking and tobacco use, and 2.0% reported current drinking and marijuana use. Discussion During 2015–2018, approximately half of all pregnant respondents who reported current drinking (drinking in the past 30 days) (9.8%) also reported binge drinking (4.5%). Among pregnant females who reported current drinking, 38.2% also reported current use of one or more other substances, including tobacco, marijuana, opioids, and other substances. The estimates of current drinking and binge drinking among pregnant females are consistent with recent analyses using data from the 2015–2017 Behavioral Risk Factor Surveillance System, which reported current drinking and binge drinking estimates of 11.5% and 3.9%, respectively, among pregnant respondents aged 18–44 years ( 3 ). The current analysis adds to previous findings by including trimester-specific estimates showing higher self-reported drinking in first trimester respondents, suggesting that some respondents who drank before pregnancy might have quit by mid-to-late pregnancy, and by providing estimates indicating that co-use of other substances is common. Few population-based reports consider co-use of other substances among pregnant females who drink alcohol. In this report, current drinking overall and in combination with one or more other substances were substantially lower than past 12 months drinking, suggesting that females decrease their use after they know they are pregnant. Alcohol exposure during pregnancy can adversely affect fetal development, resulting in behavioral disorders, impaired intellectual development, and birth defects ( 1 ). It also has been associated with miscarriage and stillbirth ( 4 ). Although supporting data are sparse, alcohol exposure combined with exposure to other substances could worsen pregnancy outcomes. Prenatal exposure to substances included in this analysis has been associated with adverse health outcomes, including preterm birth, sudden infant death syndrome, and preterm-related death (exposure to tobacco) ( 5 ); low birth weight (tobacco, marijuana) ( 5 , 6 ); and altered fetal brain development (tobacco, marijuana) ( 5 – 8 ). A review of prenatal substance exposure and neuroimaging suggests that in utero exposure to substances other than alcohol, including marijuana, nicotine, cocaine, methamphetamine, opioids, or combinations of substances, is associated with long-term effects on cognition and with altered brain connectivity and white matter deficits ( 9 ). The findings in this report are subject to at least four limitations. First, data are self-reported and therefore subject to social desirability bias; respondents might underreport substance use because of social stigma and legal implications. Second, because NSDUH only ascertains past 12 months and past 30 days substance use in a cross-sectional sample, patterns across individual pregnancies are unknown. Estimates of any substance use during the length of an entire pregnancy would likely be higher than estimates of past 30 days use. Third, limited sample size necessitated the suppression of some prevalence estimates. Finally, some pregnancies might not have been recognized at the time of the interview, resulting in misclassification by pregnancy status. Alcohol use and other substance use presumably are lower in recognized than in unrecognized pregnancies, resulting in underestimation of exposure levels. The U.S. Preventive Services Task Force recommends alcohol screening and brief behavioral counseling in primary care settings for all adults aged ≥18 years ( 10 ). ACOG recommends alcohol use screening for all females seeking obstetric-gynecologic care and counseling patients that there is no known safe level of alcohol use during pregnancy ( 2 ). ACOG also recommends routine universal screening for substance use disorders with validated screening tools or through conversations with patients. Although ACOG does not have recommendations specific to polysubstance use, the findings of this report indicate that a substantial percentage of females who use alcohol during early pregnancy also use one or more other substances, especially tobacco or marijuana. Females could benefit from screening and interventions in pregnancy to reduce alcohol and polysubstance use and from referral for those in need of treatment. Successful reduction in substance exposures during pregnancy could improve the health of mothers and their children. Summary What is already known about this topic? Drinking alcohol during pregnancy can cause miscarriage, stillbirth, and fetal alcohol spectrum disorders; however, approximately one in nine pregnant females report current drinking. Little is known about the co-use of other substances by females who drink during pregnancy. What is added by this report? Pregnant respondents in the first trimester reported higher current alcohol use than respondents in the second or third trimester. Among first trimester respondents, 19.6% reported current alcohol use and 10.5% reported binge drinking; among second or third trimester respondents, current drinking and binge drinking were reported by 4.7% and 1.4%, respectively. Approximately 40% of pregnant females reporting current drinking also reported current use of other substances. What are the implications for public health? Co-use of other substances is common among females who drink alcohol during pregnancy. Screening and interventions for alcohol and other substances in pregnancy could improve the health of mothers and their children.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis

          Objective To assess the effects of use of cannabis during pregnancy on maternal and fetal outcomes. Data sources 7 electronic databases were searched from inception to 1 April 2014. Studies that investigated the effects of use of cannabis during pregnancy on maternal and fetal outcomes were included. Study selection Case–control studies, cross-sectional and cohort studies were included. Data extraction and synthesis Data synthesis was undertaken via systematic review and meta-analysis of available evidence. All review stages were conducted independently by 2 reviewers. Main outcomes and measures Maternal, fetal and neonatal outcomes up to 6 weeks postpartum after exposure to cannabis. Meta-analyses were conducted on variables that had 3 or more studies that measured an outcome in a consistent manner. Outcomes for which meta-analyses were conducted included: anaemia, birth weight, low birth weight, neonatal length, placement in the neonatal intensive care unit, gestational age, head circumference and preterm birth. Results 24 studies were included in the review. Results of the meta-analysis demonstrated that women who used cannabis during pregnancy had an increase in the odds of anaemia (pooled OR (pOR)=1.36: 95% CI 1.10 to 1.69) compared with women who did not use cannabis during pregnancy. Infants exposed to cannabis in utero had a decrease in birth weight (low birth weight pOR=1.77: 95% CI 1.04 to 3.01; pooled mean difference (pMD) for birth weight=109.42 g: 38.72 to 180.12) compared with infants whose mothers did not use cannabis during pregnancy. Infants exposed to cannabis in utero were also more likely to need placement in the neonatal intensive care unit compared with infants whose mothers did not use cannabis during pregnancy (pOR=2.02: 1.27 to 3.21). Conclusions and relevance Use of cannabis during pregnancy may increase adverse outcomes for women and their neonates. As use of cannabis gains social acceptance, pregnant women and their medical providers could benefit from health education on potential adverse effects of use of cannabis during pregnancy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults

            Excessive alcohol use is one of the most common causes of premature mortality in the United States. From 2006 to 2010, an estimated 88 000 alcohol-attributable deaths occurred annually in the United States, caused by both acute conditions (eg, injuries from motor vehicle collisions) and chronic conditions (eg, alcoholic liver disease). Alcohol use during pregnancy is also one of the major preventable causes of birth defects and developmental disabilities.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Maternal Marijuana Use and Adverse Neonatal Outcomes

              To estimate whether marijuana use in pregnancy increases risks for adverse neonatal outcomes and clarify if any increased risk is attributable to marijuana use itself or to confounding factors such as tobacco use.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb. Mortal. Wkly. Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                07 August 2020
                07 August 2020
                : 69
                : 31
                : 1009-1014
                Affiliations
                Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, CDC; Eagle Global Scientific, LLC, San Antonio, Texas; Division of Overdose Prevention, National Center for Injury Prevention and Control, CDC; Office of the Director, National Center on Birth Defects and Developmental Disabilities, CDC; Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.
                Author notes
                Corresponding author: Lucinda J. England, lbe9@ 123456cdc.gov , 770-488-6266.
                Article
                mm6931a1
                10.15585/mmwr.mm6931a1
                7454897
                32759915
                00a8094e-ae92-43ef-aa68-33ae05e872bc

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article